The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Research Report 2025
Synopsis
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The global Anti-VEGF Drugs for Angiogenesis-related Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Drugs for Angiogenesis-related Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Drugs for Angiogenesis-related Disease.
Report Scope
The Anti-VEGF Drugs for Angiogenesis-related Disease market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Drugs for Angiogenesis-related Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Rongchang Biology
Youzhiyou Bio
Segment by Type
Ranibizumab
Brolucizumab
Aflibercept
Conbercept
Faricimab
Others
Segment by Application
Tumor
Eye Diseases
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Drugs for Angiogenesis-related Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The global Anti-VEGF Drugs for Angiogenesis-related Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Drugs for Angiogenesis-related Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Drugs for Angiogenesis-related Disease.
Report Scope
The Anti-VEGF Drugs for Angiogenesis-related Disease market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Drugs for Angiogenesis-related Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Rongchang Biology
Youzhiyou Bio
Segment by Type
Ranibizumab
Brolucizumab
Aflibercept
Conbercept
Faricimab
Others
Segment by Application
Tumor
Eye Diseases
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Drugs for Angiogenesis-related Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Overview
1.1 Product Overview and Scope of Anti-VEGF Drugs for Angiogenesis-related Disease
1.2 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Type
1.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value Comparison by Type (2024-2030)
1.2.2 Ranibizumab
1.2.3 Brolucizumab
1.2.4 Aflibercept
1.2.5 Conbercept
1.2.6 Faricimab
1.2.7 Others
1.3 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Application
1.3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value by Application: (2024-2030)
1.3.2 Tumor
1.3.3 Eye Diseases
1.3.4 Others
1.4 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2030
1.4.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2030
1.4.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-VEGF Drugs for Angiogenesis-related Disease Market Competition by Manufacturers
2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturers (2019-2024)
2.4 Global Anti-VEGF Drugs for Angiogenesis-related Disease Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, Product Type & Application
2.7 Anti-VEGF Drugs for Angiogenesis-related Disease Market Competitive Situation and Trends
2.7.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Drugs for Angiogenesis-related Disease Players Market Share by Revenue
2.7.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Drugs for Angiogenesis-related Disease Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region: 2019-2030
3.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region: 2019-2024
3.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region: 2025-2030
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region: 2019-2030
3.3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region: 2019-2024
3.3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region: 2025-2030
3.4 North America Anti-VEGF Drugs for Angiogenesis-related Disease Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2030)
3.4.3 North America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2030)
3.5.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2030)
3.7.3 Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2030)
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2025-2030)
4.1.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2030)
4.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2019-2030)
4.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2019-2024)
4.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2025-2030)
4.2.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2030)
4.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2030)
5.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024)
5.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2025-2030)
5.1.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2030)
5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2019-2030)
5.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2019-2024)
5.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2025-2030)
5.2.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2019-2030)
5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Genentech
6.3.1 Genentech Corporation Information
6.3.2 Genentech Description and Business Overview
6.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.3.5 Genentech Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Coherus BioSciences Inc.
6.5.1 Coherus BioSciences Inc. Corporation Information
6.5.2 Coherus BioSciences Inc. Description and Business Overview
6.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.5.5 Coherus BioSciences Inc. Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Qilu Pharmaceutical Co.,Ltd.
6.6.1 Qilu Pharmaceutical Co.,Ltd. Corporation Information
6.6.2 Qilu Pharmaceutical Co.,Ltd. Description and Business Overview
6.6.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
6.8 Innovent Biologics
6.8.1 Innovent Biologics Corporation Information
6.8.2 Innovent Biologics Description and Business Overview
6.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.8.5 Innovent Biologics Recent Developments/Updates
6.9 Anke Biotechnology
6.9.1 Anke Biotechnology Corporation Information
6.9.2 Anke Biotechnology Description and Business Overview
6.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.9.5 Anke Biotechnology Recent Developments/Updates
6.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
6.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Corporation Information
6.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Description and Business Overview
6.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
6.11 Chengdu Kanghong Pharmaceutical Group
6.11.1 Chengdu Kanghong Pharmaceutical Group Corporation Information
6.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Description and Business Overview
6.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
6.12 Rongchang Biology
6.12.1 Rongchang Biology Corporation Information
6.12.2 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Description and Business Overview
6.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.12.5 Rongchang Biology Recent Developments/Updates
6.13 Youzhiyou Bio
6.13.1 Youzhiyou Bio Corporation Information
6.13.2 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Description and Business Overview
6.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolio
6.13.5 Youzhiyou Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Chain Analysis
7.2 Anti-VEGF Drugs for Angiogenesis-related Disease Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Drugs for Angiogenesis-related Disease Production Mode & Process
7.4 Anti-VEGF Drugs for Angiogenesis-related Disease Sales and Marketing
7.4.1 Anti-VEGF Drugs for Angiogenesis-related Disease Sales Channels
7.4.2 Anti-VEGF Drugs for Angiogenesis-related Disease Distributors
7.5 Anti-VEGF Drugs for Angiogenesis-related Disease Customers
8 Anti-VEGF Drugs for Angiogenesis-related Disease Market Dynamics
8.1 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Trends
8.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
8.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market Challenges
8.4 Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Competitive Situation by Manufacturers in 2023
Table 4. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Anti-VEGF Drugs for Angiogenesis-related Disease, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Drugs for Angiogenesis-related Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Drugs for Angiogenesis-related Disease as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024) & (K Units)
Table 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2019-2024)
Table 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2025-2030) & (K Units)
Table 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2025-2030)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2019-2024)
Table 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2025-2030)
Table 25. North America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 27. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2025-2030) & (K Units)
Table 28. North America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 32. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2025-2030) & (K Units)
Table 33. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units) by Type (2019-2024)
Table 51. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units) by Type (2025-2030)
Table 52. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Table 53. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2025-2030)
Table 54. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2024)
Table 57. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2025-2030)
Table 58. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Type (2019-2024)
Table 59. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Type (2025-2030)
Table 60. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units) by Application (2019-2024)
Table 61. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units) by Application (2025-2030)
Table 62. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Table 63. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2025-2030)
Table 64. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2019-2024)
Table 67. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2025-2030)
Table 68. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Application (2019-2024)
Table 69. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Application (2025-2030)
Table 70. Roche Corporation Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 74. Roche Recent Developments/Updates
Table 75. Bayer Corporation Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 79. Bayer Recent Developments/Updates
Table 80. Genentech Corporation Information
Table 81. Genentech Description and Business Overview
Table 82. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 84. Genentech Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 89. Novartis Recent Developments/Updates
Table 90. Coherus BioSciences Inc. Corporation Information
Table 91. Coherus BioSciences Inc. Description and Business Overview
Table 92. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 94. Coherus BioSciences Inc. Recent Developments/Updates
Table 95. Regeneron Corporation Information
Table 96. Regeneron Description and Business Overview
Table 97. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 99. Regeneron Recent Developments/Updates
Table 100. Qilu Pharmaceutical Co.,Ltd. Corporation Information
Table 101. Qilu Pharmaceutical Co.,Ltd. Description and Business Overview
Table 102. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 104. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 105. Innovent Biologics Corporation Information
Table 106. Innovent Biologics Description and Business Overview
Table 107. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 109. Innovent Biologics Recent Developments/Updates
Table 110. Anke Biotechnology Corporation Information
Table 111. Anke Biotechnology Description and Business Overview
Table 112. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 114. Anke Biotechnology Recent Developments/Updates
Table 115. Shenzhen Kangzhe Pharmaceutical Co Ltd Corporation Information
Table 116. Shenzhen Kangzhe Pharmaceutical Co Ltd Description and Business Overview
Table 117. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 119. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 120. Chengdu Kanghong Pharmaceutical Group Corporation Information
Table 121. Chengdu Kanghong Pharmaceutical Group Description and Business Overview
Table 122. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 124. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 125. Rongchang Biology Corporation Information
Table 126. Rongchang Biology Description and Business Overview
Table 127. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 129. Rongchang Biology Recent Developments/Updates
Table 130. Youzhiyou Bio Corporation Information
Table 131. Youzhiyou Bio Description and Business Overview
Table 132. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product
Table 134. Youzhiyou Bio Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Anti-VEGF Drugs for Angiogenesis-related Disease Distributors List
Table 138. Anti-VEGF Drugs for Angiogenesis-related Disease Customers List
Table 139. Anti-VEGF Drugs for Angiogenesis-related Disease Market Trends
Table 140. Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
Table 141. Anti-VEGF Drugs for Angiogenesis-related Disease Market Challenges
Table 142. Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share by Type in 2023 & 2030
Figure 4. Ranibizumab Product Picture
Figure 5. Brolucizumab Product Picture
Figure 6. Aflibercept Product Picture
Figure 7. Conbercept Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Others Product Picture
Figure 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share by Application in 2023 & 2030
Figure 12. Tumor
Figure 13. Eye Diseases
Figure 14. Others
Figure 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size (2019-2030) & (US$ Million)
Figure 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales (2019-2030) & (K Units)
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (US$/Unit) & (2019-2030)
Figure 19. Anti-VEGF Drugs for Angiogenesis-related Disease Report Years Considered
Figure 20. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Share by Manufacturers in 2023
Figure 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Anti-VEGF Drugs for Angiogenesis-related Disease Players: Market Share by Revenue in 2023
Figure 23. Anti-VEGF Drugs for Angiogenesis-related Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2030)
Figure 26. North America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2030)
Figure 27. United States Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2030)
Figure 30. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2030)
Figure 31. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Netherlands Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2019-2030)
Figure 38. China Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. China Taiwan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2030)
Figure 46. Latin America Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Anti-VEGF Drugs for Angiogenesis-related Disease by Type (2019-2030)
Figure 56. Global Revenue Market Share of Anti-VEGF Drugs for Angiogenesis-related Disease by Type (2019-2030)
Figure 57. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Anti-VEGF Drugs for Angiogenesis-related Disease by Application (2019-2030)
Figure 59. Global Revenue Market Share of Anti-VEGF Drugs for Angiogenesis-related Disease by Application (2019-2030)
Figure 60. Global Anti-VEGF Drugs for Angiogenesis-related Disease Price (US$/Unit) by Application (2019-2030)
Figure 61. Anti-VEGF Drugs for Angiogenesis-related Disease Value Chain
Figure 62. Anti-VEGF Drugs for Angiogenesis-related Disease Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
